SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
- PMID: 34343274
- DOI: 10.1210/endocr/bqab157
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Abstract
Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted tubule to decrease blood sugar. Several animal studies revealed that SGLT-2 is profoundly involved in the inflammatory response, fibrogenesis, and regulation of numerous intracellular signaling pathways. Likewise, SGLT-2 inhibitors markedly attenuated inflammation and fibrogenesis and improved the function of damaged organ in animal studies, observational studies, and clinical trials. SGLT-2 inhibitors can decrease blood pressure and ameliorate hypertriglyceridemia and obesity. Likewise, they improve the outcome of cardiovascular diseases such as heart failure, arrhythmias, and ischemic heart disease. SGLT-2 inhibitors are associated with lower cardiovascular and all-cause mortality as well. Meanwhile, they protect against nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, acute kidney injury, and improve micro- and macroalbuminuria. SGLT-2 inhibitors can reprogram numerous signaling pathways to improve NAFLD, cardiovascular diseases, and renal diseases. For instance, they enhance lipolysis, ketogenesis, mitochondrial biogenesis, and autophagy while they attenuate the renin-angiotensin-aldosterone system, lipogenesis, endoplasmic reticulum stress, oxidative stress, apoptosis, and fibrogenesis. This review explains the beneficial effects of SGLT-2 inhibitors on NAFLD and cardiovascular and renal diseases and dissects the underlying molecular mechanisms in detail. This narrative review explains the beneficial effects of SGLT-2 inhibitors on NAFLD and cardiovascular and renal diseases using the results of latest observational studies, clinical trials, and meta-analyses. Thereafter, it dissects the underlying molecular mechanisms involved in the clinical effects of SGLT-2 inhibitors on these diseases.
Keywords: SGLT-2 inhibitors; autophagy; fibrosis; inflammation; ketogenesis; molecular mechanism.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.Front Endocrinol (Lausanne). 2021 Dec 7;12:768850. doi: 10.3389/fendo.2021.768850. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34950104 Free PMC article. Review.
-
The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease.Diabetes Obes Metab. 2025 Feb;27(2):457-467. doi: 10.1111/dom.16043. Epub 2024 Nov 7. Diabetes Obes Metab. 2025. PMID: 39508115 Review.
-
An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.Curr Diabetes Rev. 2024;20(2):e250523217349. doi: 10.2174/1573399820666230525150437. Curr Diabetes Rev. 2024. PMID: 37231725
-
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.Eur J Pharmacol. 2021 Sep 15;907:174272. doi: 10.1016/j.ejphar.2021.174272. Epub 2021 Jun 17. Eur J Pharmacol. 2021. PMID: 34147478 Review.
-
A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.Ann Pharmacother. 2021 Jan;55(1):65-79. doi: 10.1177/1060028020935105. Epub 2020 Jun 22. Ann Pharmacother. 2021. PMID: 32571083
Cited by
-
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions.Res Sq [Preprint]. 2023 Jul 21:rs.3.rs-3112506. doi: 10.21203/rs.3.rs-3112506/v1. Res Sq. 2023. Update in: Cell Biosci. 2024 Feb 22;14(1):27. doi: 10.1186/s13578-024-01203-x. PMID: 37502997 Free PMC article. Updated. Preprint.
-
Impact of Acute Kidney Injury, Co-Existing with and without Chronic Kidney Disease on the Short-Term Adverse Outcomes Following Atherosclerotic Cardiovascular Disease Events in Patients with Diabetes.J Multidiscip Healthc. 2025 Apr 12;18:2019-2037. doi: 10.2147/JMDH.S515884. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40242080 Free PMC article.
-
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions.Cell Biosci. 2024 Feb 22;14(1):27. doi: 10.1186/s13578-024-01203-x. Cell Biosci. 2024. PMID: 38388523 Free PMC article.
-
Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling pathway in rats.Toxicol Res. 2023 Oct 3;40(1):139-151. doi: 10.1007/s43188-023-00204-1. eCollection 2024 Jan. Toxicol Res. 2023. PMID: 38223670 Free PMC article.
-
Relationship between liver and cardiometabolic health in type 1 diabetes.Front Endocrinol (Lausanne). 2024 Nov 13;15:1505430. doi: 10.3389/fendo.2024.1505430. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39605938 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical